JACS | New Direction for ADC: Triggerable Probiotic-Drug Conjugates
Ulcerative colitis (UC) is a chronic, recurrent inflammatory bowel disease that not only significantly reduces the quality of life for patients but also sharply increases the risk of colorectal cancer (CAC) due to prolonged inflammation. Currently, oral probiotics are considered a promising biological therapy for UC due to their advantages in regulating gut microbiota and … Read more